Research progress of microRNA in treatment of triple negative breast cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LIU Huan ¹ , LI Hongchang ² , CHEN Yafeng ¹ , GAO Lei ¹ , LI Jie ¹ ,  FENG Dianxu ¹

1. Department of General Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, P. R. China;
2. Department of General Surgery, Minhang District Central Hospital, Shanghai 201100, P. R. China;

Corresponding author：

FENG Dianxu, Email: fdianxu@sohu.com

Keywords：

triple negative breast cancer; microRNA; epithelial-mesenchymal transition

DOI：

10.7507/1007-9424.201905033

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To understand current research progress of microRNA (miRNA) in pathogenesis of triple-negative breast cancer (TNBC), and to provide reference for understanding pathogenesis and treatment of TNBC.Method Theresearch progress of relationship of TNBC and miRNA was reviewed by reading relevant literatures at home and abroad in recent years.Results The miRNAs were involved in a variety of biological processes, including the cell proliferation, apoptosis, autophagy, differentiation, metastasis, etc., and played an important role in the cancer initiation and metastasis. Therefore, researchers had attempted to treat and prevent the TNBC by targeting miRNAs. At present, there had been a large number of reports that the miRNAs played a key role in TNBC, which were classified as the anti-oncogene and oncogene, and was associated with metastasis and prognosis of TNBC.Conclusion miRNA is very important in pathogenesis of TNBC. Mechanism of studying miRNA is necessary for treatment and prevention of TNBC.

Citation： LIU Huan, LI Hongchang, CHEN Yafeng, GAO Lei, LI Jie, FENG Dianxu. Research progress of microRNA in treatment of triple negative breast cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(1): 103-106. doi: 10.7507/1007-9424.201905033 Copy

1.	Bhattacharya R, Banerjee K, Mukherjee N, et al. From molecular insight to therapeutic strategy: The holistic approach for treating triple negative breast cancer. Pathol Res Pract, 2017, 213(3): 177-182.
2.	徐兵河. 三阴性乳腺癌综合治疗中化疗方案选择及评价. 中国实用外科杂志, 2011, 31(10): 934-937.
3.	苏淼, 白海. 微小RNA在伴遗传学异常的急性白血病中的研究进展. 白血病·淋巴瘤, 2014, 23(10): 632-635.
4.	郑健, 张雪鹏. 微小RNA在三阴性乳腺癌中的研究进展. 华北理工大学学报(医学版), 2016, 18(6): 499-504.
5.	何姝槿, 陈厚文, 熊丽霞. MicroRNA对EMT的调节作用及其与肿瘤侵袭的关系. 中国生物化学与分子生物学报, 2016, 32(11): 1197-1205.
6.	Youness RA, Hafez HM, Khallaf E, et al. The long noncoding RNA sONE represses triple-negative breast cancer aggressiveness through inducing the expression of miR-34a, miR-15a, miR-16, and let-7a. J Cell Physiol, 2019, 234(11): 20286-20297.
7.	Mohammadi-Yeganeh S, Hosseini V, Paryan M. Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo. J Cell Physiol, 2019, 234(10): 18317-18328.
8.	Tormo E, Ballester S, Adam-Artigues A, et al. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Sci Rep, 2019, 9(1): 5316.
9.	Wong CK, Gromisch C, Ozturk S, et al. MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer. Cancer Biol Ther, 2019, 20(8): 1113-1120.
10.	Shi P, Chen C, Li X, et al. MicroRNA-124 suppresses cell proliferation and invasion of triple negative breast cancer cells by targeting STAT3. Mol Med Rep, 2019, 19(5): 3667-3675.
11.	Zhao Z, Li L, Du P, et al. Transcriptional downregulation of miR-4306 serves as a new therapeutic target for triple negative breast cancer. Theranostics, 2019, 9(5): 1401-1416.
12.	Liu X, Wang J, Zhang G. miR-4458 regulates cell proliferation and apoptosis through targeting SOCS1 in triple-negative breast cancer. J Cell Biochem, 2019, 120(8): 12943-12948.
13.	Shi Z, Li Y, Qian X, et al. MiR-340 inhibits triple-negative breast cancer progression by reversing EZH2 mediated miRNAs dysregulated expressions. J Cancer, 2017, 8(15): 3037-3048.
14.	Toda H, Kurozumi S, Kijima Y, et al. Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3. J Hum Genet, 2018, 63(12): 1197-1210.
15.	Thakur S, Grover RK, Gupta S, et al. Identification of specific miRNAsignature in paired sera and tissue samples of Indian women with triple negative breast cancer. PLoS One, 2016, 11(7): e0158946.
16.	Fang H, Xie J, Zhang M, et al. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res, 2017, 9(3): 953-961.
17.	Liu S, Wang Z, Liu Z, et al. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer. J Mol Cell Biol, 2018, 10(4): 302-315.
18.	Bar I, Merhi A, Abdel-Sater F, et al. The microRNA miR-210 is expressed by cancer cells but also by the tumor microenvironment in triple-negative breast cancer. J Histochem Cytochem, 2017, 65(6): 335-346.
19.	Jang MH, Kim HJ, Gwak JM, et al. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer. Hum Pathol, 2017, 68: 69-78.
20.	Kia V, Paryan M, Mortazavi Y, et al. Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells. J Cell Biochem, 2019, 120(4): 5666-5676.
21.	Song H, Li D, Wu T, et al. MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD. BMB Rep, 2018, 51(11): 602-607.
22.	Guo GC, Wang JX, Han ML, et al. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. Cell Oncol (Dordr), 2017, 40(2): 157-166.
23.	Li Z, Meng Q, Pan A, et al. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. Oncotarget, 2017, 8(12): 19455-19466.
24.	Piasecka D, Braun M, Kordek R, et al. MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol, 2018, 144(8): 1401-1411.
25.	Cantini L, Bertoli G, Cava C, et al. Identification of microRNA clusterscooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer. Nucleic Acids Res, 2019, 47(5): 2205-2215.
26.	Kong P, Chen L, Yu M, et al. miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer. Cell Death Dis, 2018, 9(11): 1059.
27.	Wang X, Qiu H, Tang R, et al. miR-30a inhibits epithelial-mesenchymal transition and metastasis in triple-negative breast cancer by targeting ROR1. Oncol Rep, 2018, 39(6): 2635-2643.
28.	di Gennaro A, Damiano V, Brisotto G, et al. A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness. Cell Death Differ, 2018, 25(12): 2165-2180.
29.	Son D, Kim Y, Lim S, et al. miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer. Cancer Lett, 2019, 454: 224-233.
30.	Tao W, Wang C, Zhu B, et al. LncRNA DANCR contributes to tumor progression via targetting miR-216a-5p in breast cancer: lncRNA DANCR contributes to tumor progression. Biosci Rep, 2019, 39(4): pii: BSR20181618.
31.	Song X, Liu Z, Yu Z. LncRNA NEF is downregulated in triple negative breast cancer and correlated with poor prognosis. Acta Biochim Biophys Sin (Shanghai), 2019, 51(4): 386-392.
32.	Hajalirezay Yazdi S, Paryan M, Mohammadi-Yeganeh S. An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets MET and AXL in triple-negative breast cancer. Cell Mol Biol Lett, 2018, 23: 51.
33.	Xu JZ, Shao CC, Wang XJ, et al. circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. Cell Death Dis, 2019, 10(3): 175.
34.	Tang H, Huang X, Wang J, et al. circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Mol Cancer, 2019, 18(1): 23.

1. Bhattacharya R, Banerjee K, Mukherjee N, et al. From molecular insight to therapeutic strategy: The holistic approach for treating triple negative breast cancer. Pathol Res Pract, 2017, 213(3): 177-182.
2. 徐兵河. 三阴性乳腺癌综合治疗中化疗方案选择及评价. 中国实用外科杂志, 2011, 31(10): 934-937.
3. 苏淼, 白海. 微小RNA在伴遗传学异常的急性白血病中的研究进展. 白血病·淋巴瘤, 2014, 23(10): 632-635.
4. 郑健, 张雪鹏. 微小RNA在三阴性乳腺癌中的研究进展. 华北理工大学学报(医学版), 2016, 18(6): 499-504.
5. 何姝槿, 陈厚文, 熊丽霞. MicroRNA对EMT的调节作用及其与肿瘤侵袭的关系. 中国生物化学与分子生物学报, 2016, 32(11): 1197-1205.
6. Youness RA, Hafez HM, Khallaf E, et al. The long noncoding RNA sONE represses triple-negative breast cancer aggressiveness through inducing the expression of miR-34a, miR-15a, miR-16, and let-7a. J Cell Physiol, 2019, 234(11): 20286-20297.
7. Mohammadi-Yeganeh S, Hosseini V, Paryan M. Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo. J Cell Physiol, 2019, 234(10): 18317-18328.
8. Tormo E, Ballester S, Adam-Artigues A, et al. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Sci Rep, 2019, 9(1): 5316.
9. Wong CK, Gromisch C, Ozturk S, et al. MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer. Cancer Biol Ther, 2019, 20(8): 1113-1120.
10. Shi P, Chen C, Li X, et al. MicroRNA-124 suppresses cell proliferation and invasion of triple negative breast cancer cells by targeting STAT3. Mol Med Rep, 2019, 19(5): 3667-3675.
11. Zhao Z, Li L, Du P, et al. Transcriptional downregulation of miR-4306 serves as a new therapeutic target for triple negative breast cancer. Theranostics, 2019, 9(5): 1401-1416.
12. Liu X, Wang J, Zhang G. miR-4458 regulates cell proliferation and apoptosis through targeting SOCS1 in triple-negative breast cancer. J Cell Biochem, 2019, 120(8): 12943-12948.
13. Shi Z, Li Y, Qian X, et al. MiR-340 inhibits triple-negative breast cancer progression by reversing EZH2 mediated miRNAs dysregulated expressions. J Cancer, 2017, 8(15): 3037-3048.
14. Toda H, Kurozumi S, Kijima Y, et al. Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3. J Hum Genet, 2018, 63(12): 1197-1210.
15. Thakur S, Grover RK, Gupta S, et al. Identification of specific miRNAsignature in paired sera and tissue samples of Indian women with triple negative breast cancer. PLoS One, 2016, 11(7): e0158946.
16. Fang H, Xie J, Zhang M, et al. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res, 2017, 9(3): 953-961.
17. Liu S, Wang Z, Liu Z, et al. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer. J Mol Cell Biol, 2018, 10(4): 302-315.
18. Bar I, Merhi A, Abdel-Sater F, et al. The microRNA miR-210 is expressed by cancer cells but also by the tumor microenvironment in triple-negative breast cancer. J Histochem Cytochem, 2017, 65(6): 335-346.
19. Jang MH, Kim HJ, Gwak JM, et al. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer. Hum Pathol, 2017, 68: 69-78.
20. Kia V, Paryan M, Mortazavi Y, et al. Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells. J Cell Biochem, 2019, 120(4): 5666-5676.
21. Song H, Li D, Wu T, et al. MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD. BMB Rep, 2018, 51(11): 602-607.
22. Guo GC, Wang JX, Han ML, et al. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. Cell Oncol (Dordr), 2017, 40(2): 157-166.
23. Li Z, Meng Q, Pan A, et al. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. Oncotarget, 2017, 8(12): 19455-19466.
24. Piasecka D, Braun M, Kordek R, et al. MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol, 2018, 144(8): 1401-1411.
25. Cantini L, Bertoli G, Cava C, et al. Identification of microRNA clusterscooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer. Nucleic Acids Res, 2019, 47(5): 2205-2215.
26. Kong P, Chen L, Yu M, et al. miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer. Cell Death Dis, 2018, 9(11): 1059.
27. Wang X, Qiu H, Tang R, et al. miR-30a inhibits epithelial-mesenchymal transition and metastasis in triple-negative breast cancer by targeting ROR1. Oncol Rep, 2018, 39(6): 2635-2643.
28. di Gennaro A, Damiano V, Brisotto G, et al. A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness. Cell Death Differ, 2018, 25(12): 2165-2180.
29. Son D, Kim Y, Lim S, et al. miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer. Cancer Lett, 2019, 454: 224-233.
30. Tao W, Wang C, Zhu B, et al. LncRNA DANCR contributes to tumor progression via targetting miR-216a-5p in breast cancer: lncRNA DANCR contributes to tumor progression. Biosci Rep, 2019, 39(4): pii: BSR20181618.
31. Song X, Liu Z, Yu Z. LncRNA NEF is downregulated in triple negative breast cancer and correlated with poor prognosis. Acta Biochim Biophys Sin (Shanghai), 2019, 51(4): 386-392.
32. Hajalirezay Yazdi S, Paryan M, Mohammadi-Yeganeh S. An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets MET and AXL in triple-negative breast cancer. Cell Mol Biol Lett, 2018, 23: 51.
33. Xu JZ, Shao CC, Wang XJ, et al. circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. Cell Death Dis, 2019, 10(3): 175.
34. Tang H, Huang X, Wang J, et al. circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Mol Cancer, 2019, 18(1): 23.

Previous Article
Advances in genetic etiology research of congenital chest wall deformity
Next Article
CUFF 预开窗技术治疗胸主动脉腔内修复术后近端内漏

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress of microRNA in treatment of triple negative breast cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content